Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients with cirrhosis caused by alcohol-related or metabolic dysfunction-associated steatotic liver disease MASLD. The trial aims to evaluate whether taking capsules containing faecal microbiota from healthy donors can reduce infections and mortality in these patients. This Phase 3 trial follows earlier research that showed faecal microbiota transplantation FMT delivered via endoscopy was safe and feasible, leading to the development of capsules for easier treatment administration. Participants will be randomly assigned to receive either encapsulated FMT or placebo capsules that look identical but contain no active treatment. They will take five capsules every three months over a total period of 21 months or until they develop an infection requiring hospital admission. This double-blind trial means neither participants nor study staff will know which treatment is given. The study will last up to 24 months including follow-up, monitoring effects on infection rates, liver health, immune system function, and antibiotic resistance. Throughout the trial, participants will be regularly assessed for infections, liver disease progression, hospital admissions, quality of life, mental health, alcohol use, and safety of FMT treatment. Laboratory tests will examine immune response and bacterial resistance. The primary outcome is the time until first infection needing hospital care. The study involves detailed monitoring and follow-up visits for up to two years to understand the treatments impact and safety in patients with cirrhosis.
Actively Recruiting
Researchers are studying severe diabetic macular oedema DMO, a condition where fluid builds up in the central part of the retina called the macula, leading to vision loss. The study compares two treatments for people with diabetes who have severe DMO, defined by a thickened macula of 400 microns or more. The goal is to find out if starting with anti-VEGF injections followed by subthreshold micropulse laser SML treatment when the macula thickness decreases below 400 microns is as effective and more cost-effective than continuing anti-VEGF injections alone. Participants are randomly assigned to one of two groups one receives anti-VEGF injections alone, which are given monthly at first and then every 1 to 3 months as needed the other group starts with anti-VEGF injections and switches to SML treatment every 2 to 3 months once the macula thickness is less than 400 microns. The anti-VEGF drugs used include ranibizumab, aflibercept, faricimab, and brolucizumab, and SML is a laser procedure that does not damage the macula. Treatment continues until the diabetic macular oedema clears. During the study, participants attend regular clinic visits for eye exams including optical coherence tomography OCT scans to measure macula thickness and vision tests to assess best-corrected visual acuity BCVA. Researchers also collect data on quality of life, safety, treatment use, and participant experiences. The primary outcome is vision measured at 104 weeks after randomisation. The study lasts about two years, with ongoing monitoring of treatment effects, side effects, and participant satisfaction to assess the potential for wider use of the combined treatment approach.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to follow up on patients treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. This study aims to collect data on the safety and performance of the Bearing nsPVA device in treating symptomatic uterine fibroids over a 6-month period after the procedure. Participants will have undergone uterine artery embolization using Bearing nsPVA Embolization Particles, which are specially designed polyvinyl alcohol particles used to block blood flow to uterine fibroids. The study observes outcomes without altering routine care and focuses on the devices effect in reducing blood flow to these fibroids. During the study, participants will be monitored for safety up to 30 days post-procedure and for treatment effectiveness through 6 months. Data collection includes assessments of safety events and performance outcomes related to the device, with no additional experimental treatments administered. The total participation duration is approximately 6 months following treatment.
Actively Recruiting
Researchers are investigating whether adding blood-based biomarkers, genetic testing, and digital cognitive assessments to Memory Clinic diagnostic pathways can improve early diagnosis of dementia, particularly Alzheimers disease. The study focuses on adults aged 50 and over who have been referred to a Memory Clinic. This approach aims to enhance the efficiency of dementia diagnosis and patient flow within NHS Memory Clinics across the UK. Participants will undergo several assessments including blood draws to analyze plasma phosphorylated tau-217, epigenetic markers, and APOE4 genetic status. Digital cognitive testing using the Cambridge Neuropsychological Test Automated Battery CANTAB and speech analysis will also be performed. Blood biomarker and genetic results are initially withheld and later shared with clinicians during Memory Clinic appointments. Participants will receive genetic counseling regarding APOE4 results. A follow-up assessment at 12 months includes repeat blood draws and cognitive tests, along with questionnaires monitoring psychological impacts. During the study, participants will complete baseline and follow-up visits involving blood sampling, cognitive testing, and recorded speech tasks. Researchers will collect data on clinic performance, patient feedback, health-related quality of life, and psychological well-being. Additional analyses include health economic evaluation of the biomarker approach and exploratory AI-based studies on dementia progression. The total study duration can last up to 36 months with periodic assessments and feedback collection.
Actively Recruiting
This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sapablursen when added to the current standard of care for treating Polycythemia Vera PV. This Phase 3 trial involves participants who depend on phlebotomy and meet specific diagnostic criteria for PV. The study aims to assess how well sapablursen controls the need for phlebotomy and other health measures in this condition. The study has three parts Part 1a is a 32-week period where participants receive either sapablursen or a placebo in a double-blind manner. In Part 1b, participants receive open-label sapablursen for 124 weeks following the initial phase. There is also a long-term extension phase allowing treatment for up to 156 weeks. Sapablursen and placebo are given by subcutaneous injection. Participants will undergo various assessments, including monitoring of hematocrit levels, number of phlebotomies, and patient-reported symptoms such as fatigue and myelofibrosis symptoms. The main outcome is the percentage of participants who do not need phlebotomy between weeks 20 and 32. Safety and effectiveness are followed throughout the study, which may last up to nearly five years from start to completion.
Actively Recruiting
Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy, which includes either hydroxycarbamide or interferon alpha, as first-line treatment for patients with high-risk polycythemia vera. This trial aims to assess the effectiveness and safety of these treatments in managing the disease and preventing major complications such as thrombosis and transformation to other blood disorders. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of hydroxycarbamide or any formulation of interferon alpha chosen by the investigator before randomization. The study prohibits crossover between treatment arms during the trial period. Treatment and monitoring will continue for approximately 3 years, with assessments of blood markers, symptom burden, quality of life, and adverse events. During the trial, participants will have regular visits for monitoring their health, including blood tests for JAK2 V617F allele burden, quality of life questionnaires at several time points, and evaluation of clinical events such as thrombosis, haemorrhage, and disease progression. The primary outcome measured is event-free survival, defined by the time until major complications or death within the trial duration. Safety, symptom changes, and other secondary outcomes will be assessed continuously throughout the study, which is planned to complete by 2030.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
Researchers are evaluating whether adding diffusion weighted MRI scans of the liver at diagnosis can detect more synchronous metastases than CT scans alone in patients with high risk colorectal cancer. This phase II multicenter study focuses on patients with advanced primary colorectal tumors who have no evidence of liver metastases on CT. The liver metastases found through the additional DW-MRI scans will be reviewed by a multidisciplinary team to determine appropriate management based on local protocols. Participants will undergo additional liver DW-MRI scans including T2-weighted, diffusion weighted imaging, and apparent diffusion coefficient sequences. These scans will be performed six months after surgery and then every six months for three years to monitor for liver metastases. If liver metastases are detected, treatment decisions will be made by the local multidisciplinary team following their standard procedures. During the study, participants will have regular imaging assessments to track the presence and progression of liver metastases. Researchers will analyze baseline tumor risk factors, patterns of metastatic relapse, and survival outcomes over time. The primary outcome is the detection and treatment of liver metastases as guided by local protocols, with follow-up to five years after the last patient is recruited. This study aims to improve understanding of liver disease progression in high risk colorectal cancer and assess the accuracy of DW-MRI as a screening tool.
Actively Recruiting
Researchers are evaluating the efficacy and safety of olverembatinib compared to bosutinib in patients with chronic phase chronic myeloid leukemia CML-CP. This phase 3 randomized study includes patients previously treated with at least two tyrosine kinase inhibitors TKIs and also examines olverembatinib in a single-arm group of CML-CP patients with the T315I mutation. The study addresses treatment options for patients with limited effective therapies and includes a crossover option for those meeting failure criteria while on bosutinib. Participants in Part A will be randomly assigned to receive either olverembatinib every other day or bosutinib once daily. Part B involves patients with the T315I mutation receiving olverembatinib alone. Treatment cycles are 28 days, with pharmacokinetic assessments after the first two cycles. Patients may continue treatment and be monitored for up to five years to evaluate long-term outcomes and safety. During the study, participants will undergo assessments including molecular response rates at 24 and 96 weeks, cytogenetic response evaluations at multiple intervals, and monitoring for adverse events. Researchers will also track progression-free and overall survival. Organ function and performance status will be regularly evaluated to ensure safety and treatment adherence throughout the study duration.